Close Menu Icon
Net Zero Hub
Climate Resilience Hub

Pharmathen – Double Materiality Assessment

Founded in 1969, Pharmathen has grown to become one of the largest, vertically integrated developers of complex drug delivery technologies. Pharmathen remains committed to its vision to improve people’s lives through innovation and access to affordable medicines. With best-in-class research & development capabilities, Pharmathen is currently working on one of the most extensive and advanced pipelines in the industry consisting of more than 40 products, with a focus on long-acting injectables (LAI), sustained release and ophthalmic formulations produced in its US FDA and EU approved manufacturing facilities in Greece. Pharmathen’s highly diversified product portfolio of more than 90 commercialized products is sold to 250 customers and accessed by patients in more than 90 countries worldwide.
Pharmathen logo

The Challenge

Pharmathen is committed to a CSR mission; that is to make a positive impact on the lives of people, by ensuring that they enjoy better health. It is also our commitment to embrace a culture of responsibility and integrity within the workplace. Pharmathen needed to create a database for the greenhouse emissions for Scope 3 emissions from its operations.

The Solution

CSE proceeded to the measurement for all the emissions resulting from Pharmathen Scope 3 emissions throughout 2022. The measurement of the greenhouse gas (CO2) emissions included all cars and trucks used by Pharmathen’s third parties for the transport and distribution of its products, raw materials production, as well as all its business flights.

The Benefits

Tick icon

The company minimized the risk of removal from any supply chain on environmental grounds

Tick icon

The company identified ways to minimize emissions from its operations

Tick icon

Contribution to the achievement of the 17 Sustainable Development Goals

Organizations that trust us